A Phase 2b Study of GCS-100 in Patients With Chronic Kidney Disease Caused by Diabetes

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE2

Total Enrollment

375 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-03-31

Study Completion Date

2016-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A phase 2b, placebo-controlled, randomized, double-blind, multi-center study of GCS-100 in patients with chronic kidney disease caused by diabetes. The study will enroll approximately 375 patients at multiple centers located in the United States. Study duration is 6 months. Patients will be randomly assigned 1:1:1:1 to treatment with placebo (0.9% Sodium Chloride Injection, USP), 1 mg, 3 mg, or 9 mg GCS-100. All doses of study drug will be administered via intravenous (IV) push injection once weekly for 2 months (8 weeks), then every other week for an additional 4 months (16 weeks).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Pharmacokinetics and Safety Profile of a Single Dose GZR4 in Subjects with Renal Impairment

NCT06547502

Diabetes

COMPLETED PHASE1

A Study to Test the Effect of Different Doses of BI 685509 on Kidney Function in People With Diabetic Kidney Disease

NCT04750577

Diabetic Nephropathies

COMPLETED PHASE2

Efficacy, Safety, and Tolerability of Selonsertib (GS-4997) in Participants With Diabetic Kidney Disease

NCT02177786

Diabetic Kidney Disease

COMPLETED PHASE2

CLBS201 in Patients with Chronic Kidney Disease (CKD) and Type 2 Diabetes Mellitus (T2DM)

NCT04990427

Chronic Kidney Diseases

COMPLETED PHASE1

A Comparison Of Study Drug Blood Levels After One Dose Of GSK189075 In Subjects With Normal And Reduced Kidney Function

NCT00501462

Type 2 Diabetes Mellitus Diabetes Mellitus, Type 2 Renal Insufficiency

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Galectin-3 contributes to fibrosis, is elevated in patients with ESRD, and correlates with adverse outcomes (de Boer et. al., 2011, Dang et. al., 2012, Fernandes Bertocchi et. al., 2008, Henderson et. al., 2008). Animal models with genetic knockout of galectin-3 demonstrate a reduction in structural and functional deficits in the kidney (Dang et. al., 2012, Fernandes Bertocchi et. al., 2008, Henderson et. al., 2008). GCS-100 is a galectin- 3 antagonist that has been shown to reduce fibrosis pre-clinically. Based on the role of galectin-3 and fibrosis in kidney disease, the Sponsor believes GCS-100 may be effective at treating patients with CKD caused by diabetes.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Diabetic Chronic Kidney Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

GCS-100 1 mg

Dose level 1 - administered via IV push injection weekly for 2 months, then every other week for an additional 4 months

Group Type EXPERIMENTAL

GCS-100

Intervention Type DRUG

1 mg, 3 mg, or 9 mg IV push injections

GCS-100 3 mg

Dose level 2 - administered via IV push injection weekly for 2 months, then every other week for an additional 4 months

Group Type EXPERIMENTAL

GCS-100

Intervention Type DRUG

1 mg, 3 mg, or 9 mg IV push injections

GCS-100 9 mg

Dose level 3 - administered via IV push injection weekly for 2 months, then every other week for an additional 4 months

Group Type EXPERIMENTAL

GCS-100

Intervention Type DRUG

1 mg, 3 mg, or 9 mg IV push injections

Normal Saline Solution 0.9%

Placebo - administered via IV push injection weekly for 2 months, then every other week for an additional 4 months

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

GCS-100

1 mg, 3 mg, or 9 mg IV push injections

Intervention Type DRUG

Placebo

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Patient is capable of understanding the purpose and risks of the study and is able to provide written informed consent.
2. Patient is ≥ 18 and ≤ 90 years of age.
3. Patient has a baseline eGFR of 15 to \< 45 mL/min/1.73m2, defined as the average of 2 measurements collected at Screening Visits 1 and 2, and determined using the 4-variable Modification of Diet in Renal Disease (MDRD) equation.
4. Patients with diabetic CKD diagnosis \> 12 months, and if requiring renin-angiotensin-aldosterone system (RAAS) blockade medications, must be receiving stable doses (i.e., not requiring modification) for the 3 months prior to first study drug dose.
5. Stable eGFR as measured by a less than 25% variability of each Screening value from the average of the 2 Screening values taken no less than 5 days and no more than 10 days apart.
6. Patient is willing and able to comply with all protocol requirements.
7. Female patients of childbearing potential (i.e., women who have not been surgically sterilized or who have not been post-menopausal for at least 1 year) and male patients with partners of childbearing potential must agree to use medically acceptable methods of contraception throughout the study period.

Exclusion Criteria

1. Treatment with an experimental (unlicensed) drug within 4 weeks prior to Screening visit 1.
2. Patients who are known to be allergic to citrus or have a history of any allergies associated with hypersensitivity to citrus.
3. Patients who have begun new treatment with angiotensin converting enzyme inhibitors (ACEIs), angiotensin receptor blockers (ARBs), mineralocorticoid receptor blockers (MRBs), or direct renin inhibitors (DRIs) within the 3 months prior to first dose.
4. Kidney disease known to be due to causes other than diabetes.
5. Patients diagnosed with acute kidney injury (AKI) within the 3 months prior to first dose.
6. Planned renal replacement therapy of any kind within 6 months of first study drug dose.
7. Previous solid organ transplant.
8. Evidence of persistent, uncontrolled hypertension, i.e., systolic blood pressure ≥ 160 mmHg and diastolic blood pressure ≥ 100 mmHg; or evidence of persistent, uncontrolled hypotension, i.e., systolic blood pressure ≤ 90 mmHg and diastolic blood pressure ≤ 40 mmHg at repeated measures during Screening.
9. Patients who have Screening clinical laboratory values of:

1. Hemoglobin: ≤ 9 g/dL
2. Total bilirubin: \> 1.5X the upper limit of normal (ULN)
3. ALT and/or AST: \> 2.5X ULN
4. HbA1c \> 10.5%
10. Concomitant treatment with immunosuppressive agents, except for stable use of topical agents or inhaled steroids.
11. Patients who have previously received GCS-100 as part of another clinical trial.
12. Known history of cancer (excluding non-melanoma skin cancer that is not being actively treated) within 5 years of Screening.
13. Known history of human immunodeficiency virus, active hepatitis C virus (HCV), active hepatitis B virus (HBV), or prior history of infection with HBV (HBcAb positive); if adequate hepatic function has been documented for patients with HCV or prior history of hepatitis B without evidence of cirrhosis, the Medical Monitor may approve their enrollment.
14. Clinically relevant active infection and/or a serious co-morbid medical condition, such as recent myocardial infarction (within the last 6 months), unstable angina, difficult-to-control congestive heart failure, uncontrolled hypertension, difficult-to-control cardiac arrhythmias, severe or uncontrolled chronic obstructive or chronic restrictive pulmonary disease, and/or cirrhosis.
15. Patient had major surgery within 12 weeks of first study drug dose.
16. If female, patient is pregnant or breastfeeding.
17. Patient has a concomitant disease or condition, including laboratory abnormalities, which, in the opinion of the investigator, could interfere with the conduct of the study or put the patient at unacceptable risk.

Minimum Eligible Age

18 Years

Maximum Eligible Age

90 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No